As artificial intelligence (AI) continues to be adopted by the pharmaceutical industry, regulatory bodies in the United States and other countries are evolving to tackle challenges within the industry.
The U.S. Centers for Disease Control and Prevention said it will prioritize its public health response in a revamp of its structure after months of criticism over its handling of the COVID-19 and monkeypox pandemics.
The U.S. Senate passed the Inflation Reduction Act on Sunday, with Vice President Kamala Harris casting the tie-breaking vote to settle the verdict, which was split 50-50 along party lines. The bill, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives, but with a Democratic majority, it is expected to pass before the end of the week.
At first it sounded like a bad joke. Were House Republicans actually contemplating eliminating the Orphan Drug Act tax credit?
By John Kamp New legislation to spur medical innovation through new authorities for FDA and NIH is creating a lot of buzz in the Washington medical community, most of it very […]